Harvard Pilgrim Health Care agreed to cover evolocumab (Repatha, Amgen) at a discount in the first "pay-for-performance" contract for the proprotein convertase subtilisin/kexin type 9 inhibitor, the Boston Globe reports. In August, the FDA approved evolocumab, which is an injectable medication that lowers high-density lipoprotein cholesterol.

After an extensive review, the FDA found that the long-term use of clopidogrel does not increase or decrease the overall risk of death in patients with or at risk for heart disease. The FDA, which released its findings on Nov. 6, also said clopidogrel does not increase or decrease the risk of cancer or death from cancer.

Competitive athletes who participate in team sports such as football, basketball and baseball may be able to continue to play after being diagnosed with long QT syndrome or certain heartbeat disorders, according to an expert consensus recommendation from the American College of Cardiology (ACC) and American Heart Association (AHA).

Adults enrolled in the Medicare Part D prescription drug plan did not have better outcomes after suffering an acute MI compared with those without coverage, according to a database analysis.

The death rates for heart disease, stroke and other conditions significantly declined between 1969 and 2013, according to an analysis of U.S. national vital statistics data.

Tools that help patients adhere to doctor’s recommendations improve patient outcomes—it’s simple math with a host of benefits.

Adults between 40 and 70 years old who are overweight or obese should be screened for abnormal blood glucose as part of a cardiovascular risk assessment, according to a recommendation from the U.S. Preventive Services Task Force (USPSTF).

Adults with type 2 diabetes who drank five ounces of red or white wine with dinner for two years had a modest decrease in cardiometabolic risk compared with a group that drank mineral water, according to a randomized trial.